Rita Sarkis works in digital pathology and spatial transcriptomics at the Lausanne University Hospital (CHUV). Until 2023 she was the president of the EPFL’s Scientific Staff Association (ELSA). | Illustration: Stefan Vecsey

From bench to bedside! As researchers in clinical studies, we’re absorbed by transforming our innovations into tangible solutions. These might include developing an algorithm for pathologists to establish the diagnostics of biopsies, and helping them integrate this into their daily clinical practice. It seems wonderful but, in reality, it’s far from simple. Beyond the administrative and ethical aspects, there remains a major challenge in this area which seeks to reconcile two different worlds. On the one hand, there are experimental scientists like me, and, on the other, there are medical teams.

There are two mentalities, two ways of doing things, and two different languages. We work horizontally and are attached to working together and in groups. They work vertically and are attached to the practices of a somewhat hierarchical professional setting with conveyor-belt work. This gap is often divisive. Frequently, it translates into misunderstanding and lost time.

Nevertheless, when we do manage to understand how the other thinks and works, we’ve found the key to success. It leads to new projects, created in response to translational needs and requiring experimental skills. But does it always lead to positive outcomes? Often we’re tempted to quit in light of the numerous difficulties, even when the start is full of promise. Yet this comes across as a test of trust: might they be counting on us? But does the other side make the effort to understand our point of view, our way of thinking and acting?

Sometimes, the burden seems to fall entirely on scientists. It becomes essential to pitch and sell a research project with confidence, patience and perseverance. For that, you really need to believe in it, in order to convince a doctor who is short of time for research. Some countries have promoted this exchange by systematically financing protected research time in clinics. I see that as the other key to success. It might seem mission impossible, but the enthusiasm for translation makes it all possible. Maybe we need to start there!